The clinical research industry is highly competitive due to the rapid development of pharmaceuticals and biotechnology. Businesses work in a fast paced environment where they are influenced by stringent regulations and need for novel therapies. The rise in global health challenges and an urgency for personalized drugs has driven the demand for robust clinical studies. However, clients go through difficulties like complex regulatory requirements, managing various protocols and maintaining data integrity.
Additionally, the need for rapid adaptation to technological advancements and maintaining high-quality standards amidst increasing competition adds to the complexity of delivering effective and compliant research outcomes. Clians Labs, an independent CRO based in Hyderabad, specializes in delivering reliable, high-quality clinical research services for global pharmaceutical companies, with a strong focus on quality and compliance.
Clians Labs was founded with the ambitious vision to become a leading Contract Research Organization for pharmaceutical companies worldwide. Since its inception, the company has conducted over 300 Early Phase trials, showcasing its expertise in clinical research. Initially equipped with 72 beds and 4 LCMS/MS systems, the firm has expanded its facilities to 172 beds and 12 LCMS/MS systems, reflecting its robust growth and commitment to meet escalating demands. The company has distinguished itself through its impeccable regulatory inspection history, achieving zero or minimal findings from major regulatory bodies including DCGI-India, USFDA, AEMPS-Spain, EMA-CHMP, ANVISA, UKMHRA, GCC and NPRA (Malaysia).
Driven by a team of experienced professionals and a proactive approach to industry regulations, the firm continues to build on its success, aiming to set new benchmarks in the CRO landscape.
Leading Quality in Clinical Research Worldwide
Clians offers a comprehensive range of clinical research services catering to various stages of pharmaceutical development. Its portfolio includes Early Phase trials such as Bioavailability/ Bioequivalence (BA/BE) Studies and Patient-Based Pharmacokinetic (PK) Studies. The firm also conducts Clinical Trials from Phase I through Phase IV, encompassing a broad spectrum of therapeutic areas, including bioanalytical services, biosimilars, hormonal and post-menopausal studies, medical writing, and biostatistics. The company emphasizes maintaining high-quality standards across all services, ensuring reliable and objective results.
Its services are designed to meet the diverse needs of its clients, with a focus on delivering value-added solutions efficiently and accurately. “By continuously upgrading its facilities, Quality, Procedures and embracing advanced technologies, we strive to support the global pharmaceutical industry in advancing clinical research and achieving regulatory compliance”, says Dr. Kiran Kumar Aalapati, Vice President.
Clians is a leading CRO offering comprehensive clinical research services, known for its rigorous quality, advanced technology, and global regulatory compliance
Clians distinguishes itself from other CROs through a blend of rigorous quality control, strategic planning, and a strong ethical framework. The company has rapidly scaled its operations, developing a robust Quality Management System that has earned commendations from global regulatory authorities. Unlike many competitors, it maintains a zero-tolerance policy for unethical practices and emphasizes thorough planning and detailed orientation in every project. Its infrastructure includes advanced technology and well-defined procedures, ensuring consistency and reliability. Additionally, Clians’ proactive approach to regulatory changes and continuous professional development for its team sets it apart. They leverage digital tools and automation to streamline processes, enhancing efficiency and accuracy. By focusing on comprehensive compliance with international standards and adopting a risk-based approach to problem-solving, the firm upholds its commitment to delivering high-quality, dependable clinical research services.
Clians aims to expand its footprint by exploring complex and patient-oriented clinical trials in areas like respiratory products, anesthetics, and biosimilars. Over the next five years, the company plans to scale operations and enhance its capabilities, focusing on large molecule and elemental analysis. With a vision to broaden its global market reach, the firm is dedicated to partnering with multiple sponsors and advancing its infrastructure to deliver innovative, high-quality clinical research solutions worldwide.
